Nektar Stock Slumped 50% after Phase 3 Trial in Skin Cancer with Bristol Myers Fails

seekingalpha2022-03-14

Bristol Myers Squibb (NYSE:BMY) and Nektar Therapeutics' (NASDAQ:NKTR) phase 3 trial evaluating bempegaldesleukin in combination with Opdivo (nivolumab) against Opdivo alone as a first-line treatment ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

KCKHOO
2022-03-15
KCKHOO
Like
SCLIEW
2022-03-15
SCLIEW
666
BenjiFuji
2022-03-15
BenjiFuji
Better to fail at phase 3 than realise it's a mistake at phase 4.
WaiSiong81
2022-03-15
WaiSiong81
👍
stylus
2022-03-15
stylus
Oops 😬
Chonky
2022-03-15
Chonky
Like please

Leave a comment

314

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2219398271?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2022-03-14 22:15","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"2219398271","market":"us","top_or_hot":-1,"title":"Nektar Stock Slumped 50% after Phase 3 Trial in Skin Cancer with Bristol Myers Fails","media":"seekingalpha","content":"<div>\n<p>Bristol Myers Squibb (NYSE:BMY) and Nektar Therapeutics' (NASDAQ:NKTR) phase 3 trial evaluating bempegaldesleukin in combination with Opdivo (nivolumab) against Opdivo alone as a first-line treatment ...</p>\n\n<a href=\"https://seekingalpha.com/news/3813025-nektar-stock-slumps-50-after-phase-3-trial-in-skin-cancer-with-bristol-myers-fails\">Source Link</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nektar Stock Slumped 50% after Phase 3 Trial in Skin Cancer with Bristol Myers Fails</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNektar Stock Slumped 50% after Phase 3 Trial in Skin Cancer with Bristol Myers Fails\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-03-14 22:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3813025-nektar-stock-slumps-50-after-phase-3-trial-in-skin-cancer-with-bristol-myers-fails><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Bristol Myers Squibb (NYSE:BMY) and Nektar Therapeutics' (NASDAQ:NKTR) phase 3 trial evaluating bempegaldesleukin in combination with Opdivo (nivolumab) against Opdivo alone as a first-line treatment ...</p>\n\n<a href=\"https://seekingalpha.com/news/3813025-nektar-stock-slumps-50-after-phase-3-trial-in-skin-cancer-with-bristol-myers-fails\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NKTR","symbol_name":"内克塔治疗","start_time":0,"source_url":"https://seekingalpha.com/news/3813025-nektar-stock-slumps-50-after-phase-3-trial-in-skin-cancer-with-bristol-myers-fails","article_id":"2219398271","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2219398271","pubTimestamp":1647267307,"columns":[],"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"Bristol Myers Squibb (NYSE:BMY) and Nektar Therapeutics' (NASDAQ:NKTR) phase 3 trial evaluating bemp","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"NKTR":"内克塔治疗","BK4126":"金属与玻璃容器"},"translate_title":"Bristol Myers皮肤癌3期试验失败后，Nektar股价暴跌50%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NKTR":0.9},"content_text":"Bristol Myers Squibb (NYSE:BMY) and Nektar Therapeutics' (NASDAQ:NKTR) phase 3 trial evaluating bempegaldesleukin in combination with Opdivo (nivolumab) against Opdivo alone as a first-line treatment for previously untreated unresectable or metastatic melanoma did not meet the main goals.Following an initial review of the study, dubbed PIVOT IO-001, the companies were informed that the study did not meet the main goal of progression-free survival (PFS) (the length of time a patient lives with the disease without the condition getting worse) and objective response rate (ORR).The third main objective of overall survival (OS) did not meet statistical significance at the first interim analysis.The company said that since there was no additional clinical benefit in the doublet therapy arm for PFS and ORR, they have decided to unblind the trial and to perform no additional analyses for the OS endpoint.In addition, the companies also made the decision to discontinue enrollment and unblind an ongoing PIVOT-12 study in adjuvant melanoma, which is evaluating the doublet therapy of bempegaldesleukin in combination with Opdivo compared to Opdivo monotherapy in patients at high risk for recurrence after complete resection of melanoma (a type of skin cancer).The companies noted that four other studies ongoing for bempegaldesleukin plus Opdivo in renal cell carcinoma and bladder cancer are continuing.“While we are surprised and deeply disappointed in these results for the melanoma study, we will continue to await initial results from our first two ongoing studies in renal cell carcinoma and urothelial cancer, which are currently expected in the first half of 2022,” said Jonathan Zalevsky, chief research and development officer of Nektar.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":9032110994,"gmtCreate":1647304401745,"gmtModify":1676534214052,"author":{"id":"4097285050099240","authorId":"4097285050099240","name":"KCKHOO","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"4097285050099240","authorIdStr":"4097285050099240"},"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9032110994","repostId":2219398271,"repostType":4,"repost":{"id":"2219398271","kind":"news","pubTimestamp":1647267307,"share":"https://ttm.financial/m/news/2219398271?lang=&edition=fundamental","pubTime":"2022-03-14 22:15","market":"us","language":"en","title":"Nektar Stock Slumped 50% after Phase 3 Trial in Skin Cancer with Bristol Myers Fails","url":"https://stock-news.laohu8.com/highlight/detail?id=2219398271","media":"seekingalpha","summary":"Bristol Myers Squibb (NYSE:BMY) and Nektar Therapeutics' (NASDAQ:NKTR) phase 3 trial evaluating bemp","content":"<html><head></head><body><p>Bristol Myers Squibb (NYSE:BMY) and Nektar Therapeutics&#39; (NASDAQ:NKTR) phase 3 trial evaluating bempegaldesleukin in combination with Opdivo (nivolumab) against Opdivo alone as a first-line treatment for previously untreated unresectable or metastatic melanoma did not meet the main goals.</p><p>Following an initial review of the study, dubbed PIVOT IO-001, the companies were informed that the study did not meet the main goal of progression-free survival (PFS) (the length of time a patient lives with the disease without the condition getting worse) and objective response rate (ORR).</p><p>The third main objective of overall survival (OS) did not meet statistical significance at the first interim analysis.</p><p>The company said that since there was no additional clinical benefit in the doublet therapy arm for PFS and ORR, they have decided to unblind the trial and to perform no additional analyses for the OS endpoint.</p><p>In addition, the companies also made the decision to discontinue enrollment and unblind an ongoing PIVOT-12 study in adjuvant melanoma, which is evaluating the doublet therapy of bempegaldesleukin in combination with Opdivo compared to Opdivo monotherapy in patients at high risk for recurrence after complete resection of melanoma (a type of skin cancer).</p><p>The companies noted that four other studies ongoing for bempegaldesleukin plus Opdivo in renal cell carcinoma and bladder cancer are continuing.</p><p>“While we are surprised and deeply disappointed in these results for the melanoma study, we will continue to await initial results from our first two ongoing studies in renal cell carcinoma and urothelial cancer, which are currently expected in the first half of 2022,” said Jonathan Zalevsky, chief research and development officer of Nektar.</p></body></html>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nektar Stock Slumped 50% after Phase 3 Trial in Skin Cancer with Bristol Myers Fails</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNektar Stock Slumped 50% after Phase 3 Trial in Skin Cancer with Bristol Myers Fails\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-03-14 22:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3813025-nektar-stock-slumps-50-after-phase-3-trial-in-skin-cancer-with-bristol-myers-fails><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Bristol Myers Squibb (NYSE:BMY) and Nektar Therapeutics' (NASDAQ:NKTR) phase 3 trial evaluating bempegaldesleukin in combination with Opdivo (nivolumab) against Opdivo alone as a first-line treatment ...</p>\n\n<a href=\"https://seekingalpha.com/news/3813025-nektar-stock-slumps-50-after-phase-3-trial-in-skin-cancer-with-bristol-myers-fails\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NKTR":"内克塔治疗","BK4126":"金属与玻璃容器"},"source_url":"https://seekingalpha.com/news/3813025-nektar-stock-slumps-50-after-phase-3-trial-in-skin-cancer-with-bristol-myers-fails","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"2219398271","content_text":"Bristol Myers Squibb (NYSE:BMY) and Nektar Therapeutics' (NASDAQ:NKTR) phase 3 trial evaluating bempegaldesleukin in combination with Opdivo (nivolumab) against Opdivo alone as a first-line treatment for previously untreated unresectable or metastatic melanoma did not meet the main goals.Following an initial review of the study, dubbed PIVOT IO-001, the companies were informed that the study did not meet the main goal of progression-free survival (PFS) (the length of time a patient lives with the disease without the condition getting worse) and objective response rate (ORR).The third main objective of overall survival (OS) did not meet statistical significance at the first interim analysis.The company said that since there was no additional clinical benefit in the doublet therapy arm for PFS and ORR, they have decided to unblind the trial and to perform no additional analyses for the OS endpoint.In addition, the companies also made the decision to discontinue enrollment and unblind an ongoing PIVOT-12 study in adjuvant melanoma, which is evaluating the doublet therapy of bempegaldesleukin in combination with Opdivo compared to Opdivo monotherapy in patients at high risk for recurrence after complete resection of melanoma (a type of skin cancer).The companies noted that four other studies ongoing for bempegaldesleukin plus Opdivo in renal cell carcinoma and bladder cancer are continuing.“While we are surprised and deeply disappointed in these results for the melanoma study, we will continue to await initial results from our first two ongoing studies in renal cell carcinoma and urothelial cancer, which are currently expected in the first half of 2022,” said Jonathan Zalevsky, chief research and development officer of Nektar.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9032130898,"gmtCreate":1647303279953,"gmtModify":1676534213794,"author":{"id":"4092970777728640","authorId":"4092970777728640","name":"SCLIEW","avatar":"https://static.tigerbbs.com/5da553e4d3d35db75d1caae023ca8a03","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"4092970777728640","authorIdStr":"4092970777728640"},"htmlText":"666","listText":"666","text":"666","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9032130898","repostId":2219398271,"repostType":4,"repost":{"id":"2219398271","kind":"news","pubTimestamp":1647267307,"share":"https://ttm.financial/m/news/2219398271?lang=&edition=fundamental","pubTime":"2022-03-14 22:15","market":"us","language":"en","title":"Nektar Stock Slumped 50% after Phase 3 Trial in Skin Cancer with Bristol Myers Fails","url":"https://stock-news.laohu8.com/highlight/detail?id=2219398271","media":"seekingalpha","summary":"Bristol Myers Squibb (NYSE:BMY) and Nektar Therapeutics' (NASDAQ:NKTR) phase 3 trial evaluating bemp","content":"<html><head></head><body><p>Bristol Myers Squibb (NYSE:BMY) and Nektar Therapeutics&#39; (NASDAQ:NKTR) phase 3 trial evaluating bempegaldesleukin in combination with Opdivo (nivolumab) against Opdivo alone as a first-line treatment for previously untreated unresectable or metastatic melanoma did not meet the main goals.</p><p>Following an initial review of the study, dubbed PIVOT IO-001, the companies were informed that the study did not meet the main goal of progression-free survival (PFS) (the length of time a patient lives with the disease without the condition getting worse) and objective response rate (ORR).</p><p>The third main objective of overall survival (OS) did not meet statistical significance at the first interim analysis.</p><p>The company said that since there was no additional clinical benefit in the doublet therapy arm for PFS and ORR, they have decided to unblind the trial and to perform no additional analyses for the OS endpoint.</p><p>In addition, the companies also made the decision to discontinue enrollment and unblind an ongoing PIVOT-12 study in adjuvant melanoma, which is evaluating the doublet therapy of bempegaldesleukin in combination with Opdivo compared to Opdivo monotherapy in patients at high risk for recurrence after complete resection of melanoma (a type of skin cancer).</p><p>The companies noted that four other studies ongoing for bempegaldesleukin plus Opdivo in renal cell carcinoma and bladder cancer are continuing.</p><p>“While we are surprised and deeply disappointed in these results for the melanoma study, we will continue to await initial results from our first two ongoing studies in renal cell carcinoma and urothelial cancer, which are currently expected in the first half of 2022,” said Jonathan Zalevsky, chief research and development officer of Nektar.</p></body></html>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nektar Stock Slumped 50% after Phase 3 Trial in Skin Cancer with Bristol Myers Fails</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNektar Stock Slumped 50% after Phase 3 Trial in Skin Cancer with Bristol Myers Fails\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-03-14 22:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3813025-nektar-stock-slumps-50-after-phase-3-trial-in-skin-cancer-with-bristol-myers-fails><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Bristol Myers Squibb (NYSE:BMY) and Nektar Therapeutics' (NASDAQ:NKTR) phase 3 trial evaluating bempegaldesleukin in combination with Opdivo (nivolumab) against Opdivo alone as a first-line treatment ...</p>\n\n<a href=\"https://seekingalpha.com/news/3813025-nektar-stock-slumps-50-after-phase-3-trial-in-skin-cancer-with-bristol-myers-fails\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NKTR":"内克塔治疗","BK4126":"金属与玻璃容器"},"source_url":"https://seekingalpha.com/news/3813025-nektar-stock-slumps-50-after-phase-3-trial-in-skin-cancer-with-bristol-myers-fails","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"2219398271","content_text":"Bristol Myers Squibb (NYSE:BMY) and Nektar Therapeutics' (NASDAQ:NKTR) phase 3 trial evaluating bempegaldesleukin in combination with Opdivo (nivolumab) against Opdivo alone as a first-line treatment for previously untreated unresectable or metastatic melanoma did not meet the main goals.Following an initial review of the study, dubbed PIVOT IO-001, the companies were informed that the study did not meet the main goal of progression-free survival (PFS) (the length of time a patient lives with the disease without the condition getting worse) and objective response rate (ORR).The third main objective of overall survival (OS) did not meet statistical significance at the first interim analysis.The company said that since there was no additional clinical benefit in the doublet therapy arm for PFS and ORR, they have decided to unblind the trial and to perform no additional analyses for the OS endpoint.In addition, the companies also made the decision to discontinue enrollment and unblind an ongoing PIVOT-12 study in adjuvant melanoma, which is evaluating the doublet therapy of bempegaldesleukin in combination with Opdivo compared to Opdivo monotherapy in patients at high risk for recurrence after complete resection of melanoma (a type of skin cancer).The companies noted that four other studies ongoing for bempegaldesleukin plus Opdivo in renal cell carcinoma and bladder cancer are continuing.“While we are surprised and deeply disappointed in these results for the melanoma study, we will continue to await initial results from our first two ongoing studies in renal cell carcinoma and urothelial cancer, which are currently expected in the first half of 2022,” said Jonathan Zalevsky, chief research and development officer of Nektar.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9032192415,"gmtCreate":1647303045129,"gmtModify":1676534213749,"author":{"id":"4110175785559852","authorId":"4110175785559852","name":"BenjiFuji","avatar":"https://community-static.tradeup.com/news/330f59d829009a2c318784ab2b5e6098","vip":1,"hat":"https://static.tigerbbs.com/b073a07f77dbe6b3bec6b12311fde6bd","crmLevel":5,"crmLevelSwitch":0,"idStr":"4110175785559852","authorIdStr":"4110175785559852"},"htmlText":"Better to fail at phase 3 than realise it's a mistake at phase 4.","listText":"Better to fail at phase 3 than realise it's a mistake at phase 4.","text":"Better to fail at phase 3 than realise it's a mistake at phase 4.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9032192415","repostId":2219398271,"repostType":4,"repost":{"id":"2219398271","kind":"news","pubTimestamp":1647267307,"share":"https://ttm.financial/m/news/2219398271?lang=&edition=fundamental","pubTime":"2022-03-14 22:15","market":"us","language":"en","title":"Nektar Stock Slumped 50% after Phase 3 Trial in Skin Cancer with Bristol Myers Fails","url":"https://stock-news.laohu8.com/highlight/detail?id=2219398271","media":"seekingalpha","summary":"Bristol Myers Squibb (NYSE:BMY) and Nektar Therapeutics' (NASDAQ:NKTR) phase 3 trial evaluating bemp","content":"<html><head></head><body><p>Bristol Myers Squibb (NYSE:BMY) and Nektar Therapeutics&#39; (NASDAQ:NKTR) phase 3 trial evaluating bempegaldesleukin in combination with Opdivo (nivolumab) against Opdivo alone as a first-line treatment for previously untreated unresectable or metastatic melanoma did not meet the main goals.</p><p>Following an initial review of the study, dubbed PIVOT IO-001, the companies were informed that the study did not meet the main goal of progression-free survival (PFS) (the length of time a patient lives with the disease without the condition getting worse) and objective response rate (ORR).</p><p>The third main objective of overall survival (OS) did not meet statistical significance at the first interim analysis.</p><p>The company said that since there was no additional clinical benefit in the doublet therapy arm for PFS and ORR, they have decided to unblind the trial and to perform no additional analyses for the OS endpoint.</p><p>In addition, the companies also made the decision to discontinue enrollment and unblind an ongoing PIVOT-12 study in adjuvant melanoma, which is evaluating the doublet therapy of bempegaldesleukin in combination with Opdivo compared to Opdivo monotherapy in patients at high risk for recurrence after complete resection of melanoma (a type of skin cancer).</p><p>The companies noted that four other studies ongoing for bempegaldesleukin plus Opdivo in renal cell carcinoma and bladder cancer are continuing.</p><p>“While we are surprised and deeply disappointed in these results for the melanoma study, we will continue to await initial results from our first two ongoing studies in renal cell carcinoma and urothelial cancer, which are currently expected in the first half of 2022,” said Jonathan Zalevsky, chief research and development officer of Nektar.</p></body></html>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nektar Stock Slumped 50% after Phase 3 Trial in Skin Cancer with Bristol Myers Fails</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNektar Stock Slumped 50% after Phase 3 Trial in Skin Cancer with Bristol Myers Fails\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-03-14 22:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3813025-nektar-stock-slumps-50-after-phase-3-trial-in-skin-cancer-with-bristol-myers-fails><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Bristol Myers Squibb (NYSE:BMY) and Nektar Therapeutics' (NASDAQ:NKTR) phase 3 trial evaluating bempegaldesleukin in combination with Opdivo (nivolumab) against Opdivo alone as a first-line treatment ...</p>\n\n<a href=\"https://seekingalpha.com/news/3813025-nektar-stock-slumps-50-after-phase-3-trial-in-skin-cancer-with-bristol-myers-fails\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NKTR":"内克塔治疗","BK4126":"金属与玻璃容器"},"source_url":"https://seekingalpha.com/news/3813025-nektar-stock-slumps-50-after-phase-3-trial-in-skin-cancer-with-bristol-myers-fails","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"2219398271","content_text":"Bristol Myers Squibb (NYSE:BMY) and Nektar Therapeutics' (NASDAQ:NKTR) phase 3 trial evaluating bempegaldesleukin in combination with Opdivo (nivolumab) against Opdivo alone as a first-line treatment for previously untreated unresectable or metastatic melanoma did not meet the main goals.Following an initial review of the study, dubbed PIVOT IO-001, the companies were informed that the study did not meet the main goal of progression-free survival (PFS) (the length of time a patient lives with the disease without the condition getting worse) and objective response rate (ORR).The third main objective of overall survival (OS) did not meet statistical significance at the first interim analysis.The company said that since there was no additional clinical benefit in the doublet therapy arm for PFS and ORR, they have decided to unblind the trial and to perform no additional analyses for the OS endpoint.In addition, the companies also made the decision to discontinue enrollment and unblind an ongoing PIVOT-12 study in adjuvant melanoma, which is evaluating the doublet therapy of bempegaldesleukin in combination with Opdivo compared to Opdivo monotherapy in patients at high risk for recurrence after complete resection of melanoma (a type of skin cancer).The companies noted that four other studies ongoing for bempegaldesleukin plus Opdivo in renal cell carcinoma and bladder cancer are continuing.“While we are surprised and deeply disappointed in these results for the melanoma study, we will continue to await initial results from our first two ongoing studies in renal cell carcinoma and urothelial cancer, which are currently expected in the first half of 2022,” said Jonathan Zalevsky, chief research and development officer of Nektar.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9032191044,"gmtCreate":1647302772512,"gmtModify":1676534213638,"author":{"id":"4092698747642690","authorId":"4092698747642690","name":"WaiSiong81","avatar":"https://static.tigerbbs.com/81c10c8d3ad2387a719eaa62a541371f","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"4092698747642690","authorIdStr":"4092698747642690"},"htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9032191044","repostId":2219398271,"repostType":4,"repost":{"id":"2219398271","kind":"news","pubTimestamp":1647267307,"share":"https://ttm.financial/m/news/2219398271?lang=&edition=fundamental","pubTime":"2022-03-14 22:15","market":"us","language":"en","title":"Nektar Stock Slumped 50% after Phase 3 Trial in Skin Cancer with Bristol Myers Fails","url":"https://stock-news.laohu8.com/highlight/detail?id=2219398271","media":"seekingalpha","summary":"Bristol Myers Squibb (NYSE:BMY) and Nektar Therapeutics' (NASDAQ:NKTR) phase 3 trial evaluating bemp","content":"<html><head></head><body><p>Bristol Myers Squibb (NYSE:BMY) and Nektar Therapeutics&#39; (NASDAQ:NKTR) phase 3 trial evaluating bempegaldesleukin in combination with Opdivo (nivolumab) against Opdivo alone as a first-line treatment for previously untreated unresectable or metastatic melanoma did not meet the main goals.</p><p>Following an initial review of the study, dubbed PIVOT IO-001, the companies were informed that the study did not meet the main goal of progression-free survival (PFS) (the length of time a patient lives with the disease without the condition getting worse) and objective response rate (ORR).</p><p>The third main objective of overall survival (OS) did not meet statistical significance at the first interim analysis.</p><p>The company said that since there was no additional clinical benefit in the doublet therapy arm for PFS and ORR, they have decided to unblind the trial and to perform no additional analyses for the OS endpoint.</p><p>In addition, the companies also made the decision to discontinue enrollment and unblind an ongoing PIVOT-12 study in adjuvant melanoma, which is evaluating the doublet therapy of bempegaldesleukin in combination with Opdivo compared to Opdivo monotherapy in patients at high risk for recurrence after complete resection of melanoma (a type of skin cancer).</p><p>The companies noted that four other studies ongoing for bempegaldesleukin plus Opdivo in renal cell carcinoma and bladder cancer are continuing.</p><p>“While we are surprised and deeply disappointed in these results for the melanoma study, we will continue to await initial results from our first two ongoing studies in renal cell carcinoma and urothelial cancer, which are currently expected in the first half of 2022,” said Jonathan Zalevsky, chief research and development officer of Nektar.</p></body></html>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nektar Stock Slumped 50% after Phase 3 Trial in Skin Cancer with Bristol Myers Fails</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNektar Stock Slumped 50% after Phase 3 Trial in Skin Cancer with Bristol Myers Fails\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-03-14 22:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3813025-nektar-stock-slumps-50-after-phase-3-trial-in-skin-cancer-with-bristol-myers-fails><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Bristol Myers Squibb (NYSE:BMY) and Nektar Therapeutics' (NASDAQ:NKTR) phase 3 trial evaluating bempegaldesleukin in combination with Opdivo (nivolumab) against Opdivo alone as a first-line treatment ...</p>\n\n<a href=\"https://seekingalpha.com/news/3813025-nektar-stock-slumps-50-after-phase-3-trial-in-skin-cancer-with-bristol-myers-fails\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NKTR":"内克塔治疗","BK4126":"金属与玻璃容器"},"source_url":"https://seekingalpha.com/news/3813025-nektar-stock-slumps-50-after-phase-3-trial-in-skin-cancer-with-bristol-myers-fails","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"2219398271","content_text":"Bristol Myers Squibb (NYSE:BMY) and Nektar Therapeutics' (NASDAQ:NKTR) phase 3 trial evaluating bempegaldesleukin in combination with Opdivo (nivolumab) against Opdivo alone as a first-line treatment for previously untreated unresectable or metastatic melanoma did not meet the main goals.Following an initial review of the study, dubbed PIVOT IO-001, the companies were informed that the study did not meet the main goal of progression-free survival (PFS) (the length of time a patient lives with the disease without the condition getting worse) and objective response rate (ORR).The third main objective of overall survival (OS) did not meet statistical significance at the first interim analysis.The company said that since there was no additional clinical benefit in the doublet therapy arm for PFS and ORR, they have decided to unblind the trial and to perform no additional analyses for the OS endpoint.In addition, the companies also made the decision to discontinue enrollment and unblind an ongoing PIVOT-12 study in adjuvant melanoma, which is evaluating the doublet therapy of bempegaldesleukin in combination with Opdivo compared to Opdivo monotherapy in patients at high risk for recurrence after complete resection of melanoma (a type of skin cancer).The companies noted that four other studies ongoing for bempegaldesleukin plus Opdivo in renal cell carcinoma and bladder cancer are continuing.“While we are surprised and deeply disappointed in these results for the melanoma study, we will continue to await initial results from our first two ongoing studies in renal cell carcinoma and urothelial cancer, which are currently expected in the first half of 2022,” said Jonathan Zalevsky, chief research and development officer of Nektar.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9032360290,"gmtCreate":1647295092467,"gmtModify":1676534211721,"author":{"id":"4105500280423600","authorId":"4105500280423600","name":"stylus","avatar":"https://community-static.tradeup.com/news/152354359006ffa7fa65db84071fe5ed","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"4105500280423600","authorIdStr":"4105500280423600"},"htmlText":"Oops 😬&nbsp;","listText":"Oops 😬&nbsp;","text":"Oops 😬","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9032360290","repostId":2219398271,"repostType":4,"repost":{"id":"2219398271","kind":"news","pubTimestamp":1647267307,"share":"https://ttm.financial/m/news/2219398271?lang=&edition=fundamental","pubTime":"2022-03-14 22:15","market":"us","language":"en","title":"Nektar Stock Slumped 50% after Phase 3 Trial in Skin Cancer with Bristol Myers Fails","url":"https://stock-news.laohu8.com/highlight/detail?id=2219398271","media":"seekingalpha","summary":"Bristol Myers Squibb (NYSE:BMY) and Nektar Therapeutics' (NASDAQ:NKTR) phase 3 trial evaluating bemp","content":"<html><head></head><body><p>Bristol Myers Squibb (NYSE:BMY) and Nektar Therapeutics&#39; (NASDAQ:NKTR) phase 3 trial evaluating bempegaldesleukin in combination with Opdivo (nivolumab) against Opdivo alone as a first-line treatment for previously untreated unresectable or metastatic melanoma did not meet the main goals.</p><p>Following an initial review of the study, dubbed PIVOT IO-001, the companies were informed that the study did not meet the main goal of progression-free survival (PFS) (the length of time a patient lives with the disease without the condition getting worse) and objective response rate (ORR).</p><p>The third main objective of overall survival (OS) did not meet statistical significance at the first interim analysis.</p><p>The company said that since there was no additional clinical benefit in the doublet therapy arm for PFS and ORR, they have decided to unblind the trial and to perform no additional analyses for the OS endpoint.</p><p>In addition, the companies also made the decision to discontinue enrollment and unblind an ongoing PIVOT-12 study in adjuvant melanoma, which is evaluating the doublet therapy of bempegaldesleukin in combination with Opdivo compared to Opdivo monotherapy in patients at high risk for recurrence after complete resection of melanoma (a type of skin cancer).</p><p>The companies noted that four other studies ongoing for bempegaldesleukin plus Opdivo in renal cell carcinoma and bladder cancer are continuing.</p><p>“While we are surprised and deeply disappointed in these results for the melanoma study, we will continue to await initial results from our first two ongoing studies in renal cell carcinoma and urothelial cancer, which are currently expected in the first half of 2022,” said Jonathan Zalevsky, chief research and development officer of Nektar.</p></body></html>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nektar Stock Slumped 50% after Phase 3 Trial in Skin Cancer with Bristol Myers Fails</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNektar Stock Slumped 50% after Phase 3 Trial in Skin Cancer with Bristol Myers Fails\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-03-14 22:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3813025-nektar-stock-slumps-50-after-phase-3-trial-in-skin-cancer-with-bristol-myers-fails><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Bristol Myers Squibb (NYSE:BMY) and Nektar Therapeutics' (NASDAQ:NKTR) phase 3 trial evaluating bempegaldesleukin in combination with Opdivo (nivolumab) against Opdivo alone as a first-line treatment ...</p>\n\n<a href=\"https://seekingalpha.com/news/3813025-nektar-stock-slumps-50-after-phase-3-trial-in-skin-cancer-with-bristol-myers-fails\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NKTR":"内克塔治疗","BK4126":"金属与玻璃容器"},"source_url":"https://seekingalpha.com/news/3813025-nektar-stock-slumps-50-after-phase-3-trial-in-skin-cancer-with-bristol-myers-fails","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"2219398271","content_text":"Bristol Myers Squibb (NYSE:BMY) and Nektar Therapeutics' (NASDAQ:NKTR) phase 3 trial evaluating bempegaldesleukin in combination with Opdivo (nivolumab) against Opdivo alone as a first-line treatment for previously untreated unresectable or metastatic melanoma did not meet the main goals.Following an initial review of the study, dubbed PIVOT IO-001, the companies were informed that the study did not meet the main goal of progression-free survival (PFS) (the length of time a patient lives with the disease without the condition getting worse) and objective response rate (ORR).The third main objective of overall survival (OS) did not meet statistical significance at the first interim analysis.The company said that since there was no additional clinical benefit in the doublet therapy arm for PFS and ORR, they have decided to unblind the trial and to perform no additional analyses for the OS endpoint.In addition, the companies also made the decision to discontinue enrollment and unblind an ongoing PIVOT-12 study in adjuvant melanoma, which is evaluating the doublet therapy of bempegaldesleukin in combination with Opdivo compared to Opdivo monotherapy in patients at high risk for recurrence after complete resection of melanoma (a type of skin cancer).The companies noted that four other studies ongoing for bempegaldesleukin plus Opdivo in renal cell carcinoma and bladder cancer are continuing.“While we are surprised and deeply disappointed in these results for the melanoma study, we will continue to await initial results from our first two ongoing studies in renal cell carcinoma and urothelial cancer, which are currently expected in the first half of 2022,” said Jonathan Zalevsky, chief research and development officer of Nektar.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9032312453,"gmtCreate":1647280556367,"gmtModify":1676534211407,"author":{"id":"3581920930646755","authorId":"3581920930646755","name":"Chonky","avatar":"https://static.tigerbbs.com/2b26c78fb11a9e646bce483ea1b0d6f3","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3581920930646755","authorIdStr":"3581920930646755"},"htmlText":"Like please&nbsp;","listText":"Like please&nbsp;","text":"Like please","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9032312453","repostId":2219398271,"repostType":4,"repost":{"id":"2219398271","kind":"news","pubTimestamp":1647267307,"share":"https://ttm.financial/m/news/2219398271?lang=&edition=fundamental","pubTime":"2022-03-14 22:15","market":"us","language":"en","title":"Nektar Stock Slumped 50% after Phase 3 Trial in Skin Cancer with Bristol Myers Fails","url":"https://stock-news.laohu8.com/highlight/detail?id=2219398271","media":"seekingalpha","summary":"Bristol Myers Squibb (NYSE:BMY) and Nektar Therapeutics' (NASDAQ:NKTR) phase 3 trial evaluating bemp","content":"<html><head></head><body><p>Bristol Myers Squibb (NYSE:BMY) and Nektar Therapeutics&#39; (NASDAQ:NKTR) phase 3 trial evaluating bempegaldesleukin in combination with Opdivo (nivolumab) against Opdivo alone as a first-line treatment for previously untreated unresectable or metastatic melanoma did not meet the main goals.</p><p>Following an initial review of the study, dubbed PIVOT IO-001, the companies were informed that the study did not meet the main goal of progression-free survival (PFS) (the length of time a patient lives with the disease without the condition getting worse) and objective response rate (ORR).</p><p>The third main objective of overall survival (OS) did not meet statistical significance at the first interim analysis.</p><p>The company said that since there was no additional clinical benefit in the doublet therapy arm for PFS and ORR, they have decided to unblind the trial and to perform no additional analyses for the OS endpoint.</p><p>In addition, the companies also made the decision to discontinue enrollment and unblind an ongoing PIVOT-12 study in adjuvant melanoma, which is evaluating the doublet therapy of bempegaldesleukin in combination with Opdivo compared to Opdivo monotherapy in patients at high risk for recurrence after complete resection of melanoma (a type of skin cancer).</p><p>The companies noted that four other studies ongoing for bempegaldesleukin plus Opdivo in renal cell carcinoma and bladder cancer are continuing.</p><p>“While we are surprised and deeply disappointed in these results for the melanoma study, we will continue to await initial results from our first two ongoing studies in renal cell carcinoma and urothelial cancer, which are currently expected in the first half of 2022,” said Jonathan Zalevsky, chief research and development officer of Nektar.</p></body></html>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nektar Stock Slumped 50% after Phase 3 Trial in Skin Cancer with Bristol Myers Fails</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNektar Stock Slumped 50% after Phase 3 Trial in Skin Cancer with Bristol Myers Fails\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-03-14 22:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3813025-nektar-stock-slumps-50-after-phase-3-trial-in-skin-cancer-with-bristol-myers-fails><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Bristol Myers Squibb (NYSE:BMY) and Nektar Therapeutics' (NASDAQ:NKTR) phase 3 trial evaluating bempegaldesleukin in combination with Opdivo (nivolumab) against Opdivo alone as a first-line treatment ...</p>\n\n<a href=\"https://seekingalpha.com/news/3813025-nektar-stock-slumps-50-after-phase-3-trial-in-skin-cancer-with-bristol-myers-fails\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NKTR":"内克塔治疗","BK4126":"金属与玻璃容器"},"source_url":"https://seekingalpha.com/news/3813025-nektar-stock-slumps-50-after-phase-3-trial-in-skin-cancer-with-bristol-myers-fails","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"2219398271","content_text":"Bristol Myers Squibb (NYSE:BMY) and Nektar Therapeutics' (NASDAQ:NKTR) phase 3 trial evaluating bempegaldesleukin in combination with Opdivo (nivolumab) against Opdivo alone as a first-line treatment for previously untreated unresectable or metastatic melanoma did not meet the main goals.Following an initial review of the study, dubbed PIVOT IO-001, the companies were informed that the study did not meet the main goal of progression-free survival (PFS) (the length of time a patient lives with the disease without the condition getting worse) and objective response rate (ORR).The third main objective of overall survival (OS) did not meet statistical significance at the first interim analysis.The company said that since there was no additional clinical benefit in the doublet therapy arm for PFS and ORR, they have decided to unblind the trial and to perform no additional analyses for the OS endpoint.In addition, the companies also made the decision to discontinue enrollment and unblind an ongoing PIVOT-12 study in adjuvant melanoma, which is evaluating the doublet therapy of bempegaldesleukin in combination with Opdivo compared to Opdivo monotherapy in patients at high risk for recurrence after complete resection of melanoma (a type of skin cancer).The companies noted that four other studies ongoing for bempegaldesleukin plus Opdivo in renal cell carcinoma and bladder cancer are continuing.“While we are surprised and deeply disappointed in these results for the melanoma study, we will continue to await initial results from our first two ongoing studies in renal cell carcinoma and urothelial cancer, which are currently expected in the first half of 2022,” said Jonathan Zalevsky, chief research and development officer of Nektar.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":314,"commentSize":24,"repostSize":0,"favoriteSize":1,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2219398271"}